



September 28, 2015

To Whom It May Concern:

I am writing to most enthusiastically support the promotion of Dr. Artur Jurczyszyn. He earned his MD and PhD degrees at Jagiellonian University College of Medicine. Thereafter he has carried out translational studies in hematologic malignancy, focusing on multiple myeloma, at University Hospital in Krakow. I have known Dr. Jurczyszyn personally and professionally for 10 years.

Dr. Jurczyszyn has been instrumental in establishing a cooperative myeloma network in Poland for clinical trials and correlative studies and increasing awareness, research, education, and standard of treatment of myeloma nationally. As a testament to his expertise, he has been principal investigator on clinical trials of multiple novel targeted agents in myeloma including velcade, thalidomide and lenalidomide, and carfilzomib, as well as monoclonal antibodies elotuzumab and doratumumab. These agents already have and will continue to improve the lives of myeloma patients in Poland. Moreover, he has established a Poland Myeloma Foundation to support access of patients to state-of-the-art treatments.

He has presented his work at international forums including the European Hematology Association, American Society of Hematology, and the International Myeloma Workshop. He is an excellent teacher. I have personally attended his lectures which are comprehensive and appropriately targeted to his audience. As a further testament to his clinical research and teaching expertise he has published his studies in peer-reviewed journals including *Journal of Clinical Oncology*, *Leukemia*, *Bone Marrow Transplantation*, *Leukemia Research*, *Clinical Lymphoma*, *Myeloma and Leukemia*, and *Hematologic Oncology*. Finally, he has also written authoritative reviews, further attesting to his teaching and clinical expertise in this area.

In summary, Dr. Jurczyszyn has established a myeloma center of excellence in Krakow and a myeloma clinical trial network in Poland, which has directly improved the practice of medicine in myeloma nationally. He is both nationally and internationally recognized for his expertise and an acclaimed leader in this field. I therefore support his promotion with the highest degree of enthusiasm and without reservation.

Sincerely,



Kenneth Anderson, MD